These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

698 related items for PubMed ID: 23111095

  • 1. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH, Bae SC, Song GG.
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [Abstract] [Full Text] [Related]

  • 2. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH, Bae SC, Song GG.
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [Abstract] [Full Text] [Related]

  • 3. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
    Giardina AR, Ferraro D, Ciccia F, Ferrante A, Di Stefano R, Craxì A, Triolo G.
    Clin Exp Rheumatol; 2013 Oct; 31(1):25-30. PubMed ID: 22935442
    [Abstract] [Full Text] [Related]

  • 4. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [Abstract] [Full Text] [Related]

  • 5. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
    Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N.
    J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
    [Abstract] [Full Text] [Related]

  • 6. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
    Biondo MI, Germano V, Pietrosanti M, Canzoni M, Marignani M, Stroffolini T, Salemi S, D'Amelio R.
    Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
    [Abstract] [Full Text] [Related]

  • 7. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.
    Mori S, Fujiyama S.
    World J Gastroenterol; 2015 Sep 28; 21(36):10274-89. PubMed ID: 26420955
    [Abstract] [Full Text] [Related]

  • 8. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A.
    Biol Blood Marrow Transplant; 2010 Jun 28; 16(6):809-17. PubMed ID: 20060484
    [Abstract] [Full Text] [Related]

  • 9. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
    Chung SJ, Kim JK, Park MC, Park YB, Lee SK.
    J Rheumatol; 2009 Nov 28; 36(11):2416-20. PubMed ID: 19797507
    [Abstract] [Full Text] [Related]

  • 10. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.
    Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P.
    Arthritis Care Res (Hoboken); 2010 Jun 28; 62(6):749-54. PubMed ID: 20535784
    [Abstract] [Full Text] [Related]

  • 11. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
    Fidan S, Capkın E, Arıca DA, Durak S, Okatan IE.
    Int J Rheum Dis; 2021 Feb 28; 24(2):254-259. PubMed ID: 33244900
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N, Deutsch M, Manolakopoulos S, Bitsi C, Michalakeas H, Poulakidas H, Tsironi E, Giannouli S, Papatheodoridis GV, Koskinas J, Pectasides D.
    Eur J Gastroenterol Hepatol; 2017 Jan 28; 29(1):56-60. PubMed ID: 27669175
    [Abstract] [Full Text] [Related]

  • 13. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM, Huang YH, Lee PC, Lin HC, Lee SD.
    J Clin Gastroenterol; 2009 Jan 28; 43(5):496-8. PubMed ID: 19247200
    [Abstract] [Full Text] [Related]

  • 14. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
    Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P.
    J Rheumatol; 2009 Jun 28; 36(6):1188-94. PubMed ID: 19447932
    [Abstract] [Full Text] [Related]

  • 15. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S.
    Int J Rheum Dis; 2016 May 28; 19(5):470-5. PubMed ID: 24698305
    [Abstract] [Full Text] [Related]

  • 16. Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation.
    Clarke WT, Amin SS, Papamichael K, Feuerstein JD, Cheifetz AS.
    Clin Immunol; 2018 Jun 28; 191():59-62. PubMed ID: 29601854
    [Abstract] [Full Text] [Related]

  • 17. A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy.
    Notarnicola A, Iannone F, Lopalco G, Covelli M, Lapadula G.
    Reumatismo; 2014 Mar 17; 65(6):298-301. PubMed ID: 24705034
    [Abstract] [Full Text] [Related]

  • 18. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
    Talotta R, Atzeni F, Sarzi Puttini P.
    BMC Pharmacol Toxicol; 2016 Apr 21; 17():17. PubMed ID: 27098382
    [Abstract] [Full Text] [Related]

  • 19. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.
    Cassano N, Mastrandrea V, Principi M, Loconsole F, De Tullio N, Di Leo A, Vena GA.
    J Biol Regul Homeost Agents; 2011 Apr 21; 25(2):285-9. PubMed ID: 21880218
    [Abstract] [Full Text] [Related]

  • 20. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B, Samuel D.
    Liver Int; 2011 Jan 21; 31 Suppl 1():104-10. PubMed ID: 21205146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.